for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Beyondspring Inc

BYSI.OQ

Latest Trade

18.30USD

Change

0.00(0.00%)

Volume

11,850

Today's Range

17.08

 - 

18.30

52 Week Range

13.18

 - 

25.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
18.30
Open
18.28
Volume
11,850
3M AVG Volume
1.04
Today's High
18.30
Today's Low
17.08
52 Week High
25.79
52 Week Low
13.18
Shares Out (MIL)
25.96
Market Cap (MIL)
480.08
Forward P/E
-14.91
Dividend (Yield %)
--

Latest Developments

More

Beyondspring Inc Qtrly Net Loss Per Share $0.32

BeyondSpring Provides Operational Update, Q1 Financial Results

BeyondSpring Enters Open Market Sale Agreements With Jefferies Relating To Ordinary Shares Offering Of Up To $30 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Beyondspring Inc

BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.

Industry

Biotechnology & Drugs

Contact Info

28 Liberty St Fl 39

+1.646.5284184

https://www.beyondspringpharma.com/en/

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-4.400

2018

-2.420

2019(E)

-1.240
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-1,045.47
Return on Equity (TTM)
-292.33

Latest News

Latest News

BRIEF-BeyondSpring Says Richard Brand Resigned As CFO

* BEYONDSPRING SAYS RICHARD A. BRAND RESIGNED AS CHIEF FINANCIAL OFFICER OF CO EFFECTIVE AS OF FEBRUARY 20, 2018 - SEC FILING

BRIEF-BeyondSpring Appoints Patrick Fabbio To Board As An Independent Member

* BEYONDSPRING APPOINTS LIFE SCIENCES VETERAN PATRICK FABBIO TO BOARD OF DIRECTORS AS AN INDEPENDENT MEMBER Source text for Eikon: Further company coverage:

BRIEF-BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin

* BEYONDSPRING MEETS PRIMARY OBJECTIVE IN PHASE 2 PORTION OF PHASE 2/3 TRIAL (STUDY 105) WITH PLINABULIN FOR THE PREVENTION OF DOCETAXEL CHEMOTHERAPY-INDUCED NEUTROPENIA (CIN)

BRIEF-Beyondspring Says Initiates Global Phase 2/3 Trial With Plinabulin In China

* BEYONDSPRING INITIATES GLOBAL PHASE 2/3 TRIAL WITH PLINABULIN IN CHINA FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA TO DEMONSTRATE SUPERIORITY

BRIEF-BeyondSpring qtrly loss per share $‍0.68

* BeyondSpring reports third quarter 2017 operational and financial results

BRIEF-BeyondSpring announces first patient enrolled in China

* BeyondSpring announces the first patient enrolled in China in its global phase 2/3 trial with plinabulin for the prevention of chemotherapy-induced neutropenia

BRIEF-China FDA approves ctas for Beyondspring's second global plinabulin registrational trial

* China FDA approves ctas for beyondspring’s second global plinabulin registrational trial for chemotherapy-induced neutropenia prevention

BRIEF-BeyondSpring Q1 loss per share $2.66

* Beyondspring inc qtrly basic and diluted loss per share of $2.66

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up